-
1
-
-
84950104119
-
Heart Disease and Stroke Statistics-2016 Update: a report from the American Heart Association
-
1 Mozaffarian, D., Benjamin, E.J., Go, A.S., et al. Heart Disease and Stroke Statistics-2016 Update: a report from the American Heart Association. Circulation 133 (2016), e38–e360.
-
(2016)
Circulation
, vol.133
, pp. e38-e360
-
-
Mozaffarian, D.1
Benjamin, E.J.2
Go, A.S.3
-
2
-
-
84905161219
-
Global burden of cardiovascular disease: time to implement feasible strategies and to monitor results
-
2 Fuster, V., Global burden of cardiovascular disease: time to implement feasible strategies and to monitor results. J Am Coll Cardiol 64 (2014), 520–522.
-
(2014)
J Am Coll Cardiol
, vol.64
, pp. 520-522
-
-
Fuster, V.1
-
3
-
-
84940447040
-
Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013
-
3 Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386 (2015), 743–800.
-
(2015)
Lancet
, vol.386
, pp. 743-800
-
-
-
4
-
-
2942592213
-
Cardiovascular disease in non-Western countries
-
4 Reddy, K.S., Cardiovascular disease in non-Western countries. N Engl J Med 350 (2004), 2438–2440.
-
(2004)
N Engl J Med
, vol.350
, pp. 2438-2440
-
-
Reddy, K.S.1
-
5
-
-
33644878249
-
Cardiovascular disease in the developing world and its cost-effective management
-
5 Gaziano, T.A., Cardiovascular disease in the developing world and its cost-effective management. Circulation 112 (2005), 3547–3553.
-
(2005)
Circulation
, vol.112
, pp. 3547-3553
-
-
Gaziano, T.A.1
-
6
-
-
84928036813
-
Cardiovascular drug development: is it dead or just hibernating?
-
6 Fordyce, C.B., Roe, M.T., Ahmad, T., et al. Cardiovascular drug development: is it dead or just hibernating?. J Am Coll Cardiol 65 (2015), 1567–1582.
-
(2015)
J Am Coll Cardiol
, vol.65
, pp. 1567-1582
-
-
Fordyce, C.B.1
Roe, M.T.2
Ahmad, T.3
-
7
-
-
62749084498
-
An uncertain future for cardiovascular drug development?
-
7 Garber, A.M., An uncertain future for cardiovascular drug development?. N Engl J Med 360 (2009), 1169–1171.
-
(2009)
N Engl J Med
, vol.360
, pp. 1169-1171
-
-
Garber, A.M.1
-
8
-
-
84891142213
-
Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial
-
8 Nicholls, S.J., Kastelein, J.J., Schwartz, G.G., et al. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA 311 (2014), 252–262.
-
(2014)
JAMA
, vol.311
, pp. 252-262
-
-
Nicholls, S.J.1
Kastelein, J.J.2
Schwartz, G.G.3
-
9
-
-
84903532987
-
Drug development and FDA approval, 1938-2013
-
9 Darrow, J.J., Kesselheim, A.S., Drug development and FDA approval, 1938-2013. N Engl J Med, 370, 2014, e39.
-
(2014)
N Engl J Med
, vol.370
, pp. e39
-
-
Darrow, J.J.1
Kesselheim, A.S.2
-
10
-
-
79957889347
-
The productivity crisis in pharmaceutical R&D
-
10 Pammolli, F., Magazzini, L., Riccaboni, M., The productivity crisis in pharmaceutical R&D. Nat Rev Drug Discov 10 (2011), 428–438.
-
(2011)
Nat Rev Drug Discov
, vol.10
, pp. 428-438
-
-
Pammolli, F.1
Magazzini, L.2
Riccaboni, M.3
-
11
-
-
84948712481
-
Two decades of new drug development for central nervous system disorders
-
11 Kesselheim, A.S., Hwang, T.J., Franklin, J.M., Two decades of new drug development for central nervous system disorders. Nat Rev Drug Discov 14 (2015), 815–816.
-
(2015)
Nat Rev Drug Discov
, vol.14
, pp. 815-816
-
-
Kesselheim, A.S.1
Hwang, T.J.2
Franklin, J.M.3
-
12
-
-
41449104685
-
Drug-review deadlines and safety problems
-
12 Carpenter, D., Zucker, E.J., Avorn, J., Drug-review deadlines and safety problems. N Engl J Med 358 (2008), 1354–1361.
-
(2008)
N Engl J Med
, vol.358
, pp. 1354-1361
-
-
Carpenter, D.1
Zucker, E.J.2
Avorn, J.3
-
13
-
-
33645675960
-
Estimating the cost of new drug development: is it really 802 million dollars?
-
13 Adams, C.P., Brantner, V.V., Estimating the cost of new drug development: is it really 802 million dollars?. Health Aff (Millwood) 25 (2006), 420–428.
-
(2006)
Health Aff (Millwood)
, vol.25
, pp. 420-428
-
-
Adams, C.P.1
Brantner, V.V.2
-
14
-
-
84893275211
-
Regulatory watch: where do new medicines originate from in the EU?
-
14 Lincker, H., Ziogas, C., Carr, M., Porta, N., Eichler, H.G., Regulatory watch: where do new medicines originate from in the EU?. Nat Rev Drug Discov 13 (2014), 92–93.
-
(2014)
Nat Rev Drug Discov
, vol.13
, pp. 92-93
-
-
Lincker, H.1
Ziogas, C.2
Carr, M.3
Porta, N.4
Eichler, H.G.5
-
15
-
-
84958672783
-
Vaccine pipeline has grown during the past two decades with more early-stage trials from small and medium-size companies
-
15 Hwang, T.J., Kesselheim, A.S., Vaccine pipeline has grown during the past two decades with more early-stage trials from small and medium-size companies. Health Aff (Millwood) 35 (2016), 219–226.
-
(2016)
Health Aff (Millwood)
, vol.35
, pp. 219-226
-
-
Hwang, T.J.1
Kesselheim, A.S.2
-
16
-
-
84901603869
-
Target small firms for antibiotic innovation
-
16 Hwang, T.J., Carpenter, D., Kesselheim, A.S., Target small firms for antibiotic innovation. Science 344 (2014), 967–969.
-
(2014)
Science
, vol.344
, pp. 967-969
-
-
Hwang, T.J.1
Carpenter, D.2
Kesselheim, A.S.3
-
17
-
-
84884271849
-
An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987-2011
-
17 Lanthier, M., Miller, K.L., Nardinelli, C., Woodcock, J., An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987-2011. Health Aff (Millwood) 32 (2013), 1433–1439.
-
(2013)
Health Aff (Millwood)
, vol.32
, pp. 1433-1439
-
-
Lanthier, M.1
Miller, K.L.2
Nardinelli, C.3
Woodcock, J.4
-
18
-
-
84947259792
-
Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study
-
18 Kesselheim, A.S., Wang, B., Franklin, J.M., Darrow, J.J., Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study. BMJ, 351, 2015, h4633.
-
(2015)
BMJ
, vol.351
, pp. h4633
-
-
Kesselheim, A.S.1
Wang, B.2
Franklin, J.M.3
Darrow, J.J.4
-
19
-
-
84905495729
-
The discovery of first-in-class drugs: origins and evolution
-
19 Eder, J., Sedrani, R., Wiesmann, C., The discovery of first-in-class drugs: origins and evolution. Nat Rev Drug Discov 13 (2014), 577–587.
-
(2014)
Nat Rev Drug Discov
, vol.13
, pp. 577-587
-
-
Eder, J.1
Sedrani, R.2
Wiesmann, C.3
-
20
-
-
0034687597
-
Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations: main results of the GUARDIAN trial
-
20 Théroux, P., Chaitman, B.R., Danchin, N., et al. Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations: main results of the GUARDIAN trial. Circulation 102 (2000), 3032–3038.
-
(2000)
Circulation
, vol.102
, pp. 3032-3038
-
-
Théroux, P.1
Chaitman, B.R.2
Danchin, N.3
-
21
-
-
0043166526
-
Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease
-
21 Topol, E.J., Easton, D., Harrington, R.A., et al. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation 108 (2003), 399–406.
-
(2003)
Circulation
, vol.108
, pp. 399-406
-
-
Topol, E.J.1
Easton, D.2
Harrington, R.A.3
-
22
-
-
37549062578
-
A randomised trial of a pre-synaptic stimulator of DA2-dopaminergic and alpha2-adrenergic receptors on morbidity and mortality in patients with heart failure
-
22 Torp-Pedersen, C., Køber, L., Carlsen, J.E., et al. A randomised trial of a pre-synaptic stimulator of DA2-dopaminergic and alpha2-adrenergic receptors on morbidity and mortality in patients with heart failure. Eur J Heart Fail 10 (2008), 89–95.
-
(2008)
Eur J Heart Fail
, vol.10
, pp. 89-95
-
-
Torp-Pedersen, C.1
Køber, L.2
Carlsen, J.E.3
-
23
-
-
36348975228
-
Effects of torcetrapib in patients at high risk for coronary events
-
23 Barter, P.J., Caulfield, M., Eriksson, M., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357 (2007), 2109–2122.
-
(2007)
N Engl J Med
, vol.357
, pp. 2109-2122
-
-
Barter, P.J.1
Caulfield, M.2
Eriksson, M.3
-
24
-
-
84944937913
-
Reducing LDL with PCSK9 inhibitors—the clinical benefit of lipid drugs
-
24 Everett, B.M., Smith, R.J., Hiatt, W.R., Reducing LDL with PCSK9 inhibitors—the clinical benefit of lipid drugs. N Engl J Med 373 (2015), 1588–1591.
-
(2015)
N Engl J Med
, vol.373
, pp. 1588-1591
-
-
Everett, B.M.1
Smith, R.J.2
Hiatt, W.R.3
-
25
-
-
84907087561
-
Angiotensin-neprilysin inhibition versus enalapril in heart failure
-
25 McMurray, J.J., Packer, M., Desai, A.S., et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371 (2014), 993–1004.
-
(2014)
N Engl J Med
, vol.371
, pp. 993-1004
-
-
McMurray, J.J.1
Packer, M.2
Desai, A.S.3
-
26
-
-
0037417807
-
The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation
-
26 Seidah, N.G., Benjannet, S., Wickham, L., et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A 100 (2003), 928–933.
-
(2003)
Proc Natl Acad Sci U S A
, vol.100
, pp. 928-933
-
-
Seidah, N.G.1
Benjannet, S.2
Wickham, L.3
-
27
-
-
0037603589
-
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
-
27 Abifadel, M., Varret, M., Rabès, J.P., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34 (2003), 154–156.
-
(2003)
Nat Genet
, vol.34
, pp. 154-156
-
-
Abifadel, M.1
Varret, M.2
Rabès, J.P.3
-
28
-
-
13944265645
-
Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9
-
28 Cohen, J., Pertsemlidis, A., Kotowski, I.K., Graham, R., Garcia, C.K., Hobbs, H.H., Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 37 (2005), 161–165.
-
(2005)
Nat Genet
, vol.37
, pp. 161-165
-
-
Cohen, J.1
Pertsemlidis, A.2
Kotowski, I.K.3
Graham, R.4
Garcia, C.K.5
Hobbs, H.H.6
-
29
-
-
33645103550
-
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
-
29 Cohen, J., Boerwinkle, E., Mosley, T.H. Jr., Hobbs, H.H., Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354 (2006), 1264–1272.
-
(2006)
N Engl J Med
, vol.354
, pp. 1264-1272
-
-
Cohen, J.1
Boerwinkle, E.2
Mosley, T.H.3
Hobbs, H.H.4
-
30
-
-
17244377696
-
Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9
-
30 Rashid, S., Curtis, D.E., Garuti, R., et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci U S A 102 (2005), 5374–5379.
-
(2005)
Proc Natl Acad Sci U S A
, vol.102
, pp. 5374-5379
-
-
Rashid, S.1
Curtis, D.E.2
Garuti, R.3
-
31
-
-
84876260798
-
Genetics: a gene of rare effect
-
31 Hall, S.S., Genetics: a gene of rare effect. Nature 496 (2013), 152–155.
-
(2013)
Nature
, vol.496
, pp. 152-155
-
-
Hall, S.S.1
-
32
-
-
84858638369
-
Effect of a monoclonal antibody to PCSK9 on LDL cholesterol
-
32 Stein, E.A., Mellis, S., Yancopoulos, G.D., et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 366 (2012), 1108–1118.
-
(2012)
N Engl J Med
, vol.366
, pp. 1108-1118
-
-
Stein, E.A.1
Mellis, S.2
Yancopoulos, G.D.3
-
33
-
-
50149101511
-
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
-
33 Frank-Kamenetsky, M., Grefhorst, A., Anderson, N.N., et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A 105 (2008), 11915–11920.
-
(2008)
Proc Natl Acad Sci U S A
, vol.105
, pp. 11915-11920
-
-
Frank-Kamenetsky, M.1
Grefhorst, A.2
Anderson, N.N.3
-
34
-
-
84892741671
-
Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
-
34 Fitzgerald, K., Frank-Kamenetsky, M., Shulga-Morskaya, S., et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 383 (2014), 60–68.
-
(2014)
Lancet
, vol.383
, pp. 60-68
-
-
Fitzgerald, K.1
Frank-Kamenetsky, M.2
Shulga-Morskaya, S.3
-
35
-
-
84944097535
-
A cholesterol-lowering VLP vaccine that targets PCSK9
-
35 Crossey, E., Amar, M.J., Sampson, M., et al. A cholesterol-lowering VLP vaccine that targets PCSK9. Vaccine 33 (2015), 5747–5755.
-
(2015)
Vaccine
, vol.33
, pp. 5747-5755
-
-
Crossey, E.1
Amar, M.J.2
Sampson, M.3
-
36
-
-
84959568573
-
Tribulations of recent cardiology trials, the audacity of hope, and HOPE-3
-
36 Waters, D.D., Chau, K.H., Tribulations of recent cardiology trials, the audacity of hope, and HOPE-3. Can J Cardiol 32 (2016), 275–277.
-
(2016)
Can J Cardiol
, vol.32
, pp. 275-277
-
-
Waters, D.D.1
Chau, K.H.2
-
37
-
-
84926288672
-
Accessibility of trial reports for drugs stalling in development: a systematic assessment of registered trials
-
37 Hakala, A., Kimmelman, J., Carlisle, B., Freeman, G., Fergusson, D., Accessibility of trial reports for drugs stalling in development: a systematic assessment of registered trials. BMJ, 350, 2015, h1116.
-
(2015)
BMJ
, vol.350
, pp. h1116
-
-
Hakala, A.1
Kimmelman, J.2
Carlisle, B.3
Freeman, G.4
Fergusson, D.5
-
38
-
-
84921781584
-
Sharing and reporting the results of clinical trials
-
38 Hudson, K.L., Collins, F.S., Sharing and reporting the results of clinical trials. JAMA 313 (2015), 355–356.
-
(2015)
JAMA
, vol.313
, pp. 355-356
-
-
Hudson, K.L.1
Collins, F.S.2
|